Zydus Lifesciences gets USFDA approval for Micafungin Injection

27 Oct 2022 , 07:45 AM

The generic Micafungin injectable, which is used to treat a range of fungal diseases, has got the final approval from the US health agency, according to Zydus Lifesciences, which announced this on Wednesday.

Micafungin Injection, 50 mg/vial and 100 mg/vial, single-dose vials have received FDA permission for marketing, according to a filing with the stock exchange by Zydus Lifesciences Ltd.

On the BSE, Zydus Lifesciences shares were up roughly 1% to Rs417.25.

Micafungin injection is also used to protect patients receiving stem cell transplants against fungus infections. According to the company, the medication would be produced at the group’s injectable manufacturing facility in Jarod, close to Vadodara, India.

For feedback and suggestions, write to us at [e-mail]